Neurometrix Inc Down 7.11% To $1.96 After Earnings

Neurometrix Inc (NURO) missed earnings estimates for Q3 2022 this morning.

Neurometrix Inc's earnings came in at an EPS loss of $0.23 per share. The firm's loss per share expanded by 92% since reporting a loss of $0.12 per share a year ago. Remember, earnings reported were on an adjusted basis, so they may not be comparable to prior reports and/or analyst estimates.

Revenues were upbeat at $2 million. That revenue figure represents a 4.65% decrease from the year ago quarter.

The stock is down 7.11% to $1.96 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

Trading in the five days leading up to the report earned Neurometrix Inc a Neutral Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 14.

NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment of being Medical equipment and consumables.